Back to top
more

Align Technology (ALGN)

(Real Time Quote from BATS)

$136.73 USD

136.73
1,508,925

+0.21 (0.15%)

Updated Aug 4, 2025 01:56 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 19% (46 out of 246)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Align Technology, based in California, manufactures and markets a system of clear aligner therapy, intra-oral scanners and CAD/CAM (computer-aided design and computer-aided manufacturing) digital services used in dentistry, orthodontics, and dental records storage. The clear aligner system corrects malocclusion using nearly invisible and removable appliances that gently move the tooth to a desired final position.

Zacks Equity Research

What to Expect from International Paper (IP) in Q2 Earnings?

by Zacks Equity Research

Fluctuations in actual equity market returns, changes in general interest rates are likely to hurt International Paper (IP) in Q2 earnings.

    Zacks Equity Research

    VASCO (VDSI) to Report Q2 Earnings: What's in the Offing?

    by Zacks Equity Research

    Vasco's (VDSI) focus on generating high operating margins, backed by continuous investments and a shift in the product mix with higher gross-margin products, is likely to boost its Q2 earnings.

      Zacks Equity Research

      PetMed Express (PETS) Tops Earnings, Revenue Estimates in Q1

      by Zacks Equity Research

      PetMed (PETS) initiated fiscal 2018 with better-than-expected results in the first quarter, beating both earnings and revenues.

        Zacks Equity Research

        Ecolab (ECL) to Report Q2 Earnings: Will It Pull a Surprise?

        by Zacks Equity Research

        Despite an upbeat guidance, cutthroat competition in the niche space is likely to mar Ecolab's (ECL) growth in the second quarter.

          Zacks Equity Research

          Can Cerner (CERN) Deliver a Beat this Earnings Season?

          by Zacks Equity Research

          We believe Cerner's (CERN) strong sales performance, solid portfolio and strategic initiatives have positioned it for stellar growth.

            Zacks Equity Research

            What to Expect from Anthem (ANTM) this Earnings Season?

            by Zacks Equity Research

            Anthem's (ANTM) second-quarter earnings are likely to be supported by robust medical enrollment. However, rising level of SG&A expenses might put pressure on the bottom line.

              Zacks Equity Research

              Centene (CNC) to Report Q2 Earnings: What's in the Cards?

              by Zacks Equity Research

              Centene's (CNC) second-quarter earnings are likely to be driven by Health Net buyout. However, surging level of SG&A expenses might put pressure on the bottom line.

                Zacks Equity Research

                Universal Health (UHS) Q2 Earnings: What's in the Cards?

                by Zacks Equity Research

                Universal Health's (UHS) second-quarter earnings are likely to be boosted by solid revenue growth. However, increasing cost of debt might hurt the bottom line.

                  Zacks Equity Research

                  Will Stryker (SYK) Deliver a Beat this Earnings Season?

                  by Zacks Equity Research

                  The growing adoption of Stryker's (SYK) MAKO robots is expected to drive second-quarter 2017 sales in the orthopedic and reconstructive surgery market.

                    Zacks Equity Research

                    Abbott Labs (ABT) Beats on Q2 Earnings and Sales, View Up

                    by Zacks Equity Research

                    Abbott Labs' (ABT) Q2 performance was strong on solid EPD and Medical Device growth. The stock's guidance for 2017 has also been raised.

                      Zacks Equity Research

                      What's in Store for Express Scripts (ESRX) in Q2 Earnings?

                      by Zacks Equity Research

                      Despite an upbeat guidance, cutthroat competition in the niche space is likely to mar Express Scripts' (ESRX) growth in the second quarter.

                        Zacks Equity Research

                        Align Technology (ALGN) Q2 Earnings: A Beat in the Cards?

                        by Zacks Equity Research

                        Align Technology (ALGN) might ride high in Q2 banking on growth in the Invisalign space.

                          Zacks Equity Research

                          Quest Diagnostics Closes Deal to Acquire 2 Labs in Texas

                          by Zacks Equity Research

                          Quest Diagnostics (DGX) acquires Med Fusion and Clear Point lab businesses to grow in oncology space.

                            Zacks Equity Research

                            Is a Surprise in Store for CR Bard (BCR) in Q2 Earnings?

                            by Zacks Equity Research

                            Growing adoption of the company's flagship Lutonix drug coated-balloon is expected to benefit C.R. Bard's (BCR) performance in the second quarter.

                              Zacks Equity Research

                              GNC Holdings (GNC) Q2 Earnings: Disappointment in the Cards?

                              by Zacks Equity Research

                              We do not expect GNC Holdings (GNC) to beat estimates in Q2 earnings on account of a tough competitive landscape and currency headwinds.

                                Zacks Equity Research

                                Edwards Lifesciences (EW) Q2 Earnings: A Surprise in Store?

                                by Zacks Equity Research

                                Edwards Lifesciences (EW) will likely ride high in Q2 earnings banking on continued growth in its highly advanced Transcatheter Heart Valve space.

                                  Zacks Equity Research

                                  Can Quest Diagnostics (DGX) Pull a Surprise in Q2 Earnings?

                                  by Zacks Equity Research

                                  Weak revenue per requisition performance and reimbursement pressure might dampen Quest Diagnostics' (DGX) benefits from esoteric testing business, infectious disease testing and prescription drug monitoring business growth.

                                    Zacks Equity Research

                                    Align Technology Hits a 52-Week High on Solid Prospects

                                    by Zacks Equity Research

                                    Share price of San Jose, CA-based Align Technology, Inc. (ALGN) reached a new 52-week high of $157.86 on Jul 17, eventually closing a bit lower at $156.21.

                                      Zacks Equity Research

                                      Medtronic InterStim System Shows Five-Year Positive Results

                                      by Zacks Equity Research

                                      Medtronic plc (MDT) has announced that its InterStim system provides sustained long-term efficacy and improved quality of life for overactive bladder (OAB) patients at the end of five years.

                                        Zacks Equity Research

                                        Haemonetics Plasma Arm Advances, Blood Center Sluggish

                                        by Zacks Equity Research

                                        On Jul 13, we issued an updated research report on Haemonetics Corporation (HAE).

                                          Zacks Equity Research

                                          Why Is It the Perfect Time to Buy Thermo Fisher (TMO) Stock?

                                          by Zacks Equity Research

                                          Thermo Fisher Scientific, Inc. (TMO) is on a healthy growth trajectory of late and has rallied 17.7% over the past three months.

                                            Zacks Equity Research

                                            BioTelemetry (BEAT) Acquires LifeWatch for $280 Million

                                            by Zacks Equity Research

                                            BioTelemetry Inc. (BEAT) enhances its position in the wireless medicine space, enlarges product profile and customer base in cardiac monitoring and diagnostic services with LifeWatch buyout.

                                              Zacks Equity Research

                                              Hill-Rom (HRC) at 52-Week High: What's Driving the Stock?

                                              by Zacks Equity Research

                                              Share price of Batesville, IN-based Hill-Rom Holdings, Inc. (HRC) scaled a new 52-week high of $84.17 on Jul 14.

                                                Zacks Equity Research

                                                Avantor to Acquire VWR, Consolidation Promises Global Gains

                                                by Zacks Equity Research

                                                On Jul 14, we issued an updated research report on Radnor, PA-based VWR Corporation (VWR).

                                                  Zacks Equity Research

                                                  DaVita Medical Group Buys Dr. Rahn Shaw Practices in Orlando

                                                  by Zacks Equity Research

                                                  DaVita Inc. (DVA) recently acquired Dr. Rahn Shaw's practices, Park Avenue Medical, Inc. and Winter Park Health Center, Inc., each located in Orlando.